Skip to main content

Epidemiology of Hidradenitis Suppurativa: Prevalence, Pathogenesis, and Factors Associated with the Development of HS

Abstract

Hidradenitis suppurativa is a common skin disease with an estimated prevalence of approximately 1 %. The disease is characterized by painful nodules localized mainly in the inverse body areas, such as the axillae and groin. The pathogenesis of HS is still not fully understood, but infundibular hyperkeratosis, causing follicular occlusion, is thought to be the primary event followed by rupture with an inflammatory response. Multiple factors are associated with HS, especially smoking and obesity. More recently, the genetic background and an aberrant innate immune response have gained more attention as predisposing factors. In this review, we discuss the prevalence, pathogenesis, and relevant factors influencing the development of HS.

This is a preview of subscription content, access via your institution.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.

    •• Jemec GBE. Hidradenitis suppurativa. N Engl J Med. 2012;366:158–64. This article is a comprehensive review about HS and its treatments.

    CAS  PubMed  Article  Google Scholar 

  2. 2.

    Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009;60:539–61.

    PubMed  Article  Google Scholar 

  3. 3.

    Revuz JE, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59:596–601.

    PubMed  Article  Google Scholar 

  4. 4.

    Jemec GBE, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996;35:191–4.

    CAS  PubMed  Article  Google Scholar 

  5. 5.

    Canoui-Poitrine F, Revuz JE, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol. 2009;61:51–7.

    PubMed  Article  Google Scholar 

  6. 6.

    Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereo. 2009;23:985–98.

    CAS  Article  Google Scholar 

  7. 7.

    Von der Werth JM, Williams HC. The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2000;14:389–92.

    PubMed  Article  Google Scholar 

  8. 8.

    Mengesha YM, Holcombe TC, Hansen RC. Prepubertal hidradenitis suppurativa: two case reports and review of the literature. Pediatr Dermatol. 1999;16:292–6.

    CAS  PubMed  Article  Google Scholar 

  9. 9.

    Von der Werth JM, Williams HC, Raeburn JA. The clinical genetics of hidradenitis suppurativa revisited. Br J Dermatol. 2000;142:947–53.

    Article  Google Scholar 

  10. 10.

    C-W YU, Cook MG. Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol. 1990;122:763–9.

    Article  Google Scholar 

  11. 11.

    Boer J, Weltevreden EF. Hidradenitis suppurativa or acne inversa. A clinicopathological study of early lesions. Br J Dermatol. 1996;135:721–5.

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    Van der Zee HH, de Ruiter L, Boer J, van den Broecke DG, den Hollander JC, Laman JD, et al. Alterations in leucocyte subsets and histomorphology in normal‐appearing perilesional skin and early and chronic hidradenitis suppurativa lesions. Br J Dermatol. 2012;166:98–106.

    PubMed  Article  Google Scholar 

  13. 13.

    Danby FW, Jemec GBE, Marsch WC, von Laffert M. Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support. Br J Dermatol. 2013;168:1034–9.

    CAS  PubMed  Article  Google Scholar 

  14. 14.

    von Laffert M, Helmbold P, Wohlrab J, Fiedler E, Stadie V, Marsch WC. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol. 2010;19:533–7.

    Google Scholar 

  15. 15.

    Von Laffert M, Stadie V, Wohlrab J, Marsch WC. Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol. 2011;164:367–71.

    Article  Google Scholar 

  16. 16.

    Van der Zee HH, de Ruiter L, van den Broecke DG, Dik WA, Laman JD, Prens EP. Elevated levels of tumour necrosis factor (TNF)‐α, interleukin (IL)‐1β and IL‐10 in hidradenitis suppurativa skin: a rationale for targeting TNF‐α and IL‐1β. Br J Dermatol. 2011;164:1292–8.

    PubMed  Article  Google Scholar 

  17. 17.

    Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, et al. Adalimumab for the treatment of moderate to severe hidradenitis SuppurativaA parallel randomized trial. Ann Intern Med. 2012;157:846–55.

    PubMed  Article  Google Scholar 

  18. 18.

    Mekkes JR, Bos JD. Long‐term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol. 2008;158:370–4.

    CAS  PubMed  Article  Google Scholar 

  19. 19.

    Rompel R, Petres J. Long‐term results of wide surgical excision in 106 patients with hidradenitis suppurativa. Dermatol Surg. 2000;26:638–43.

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Wollina U, Koch A, Heinig B, Kittner T, Nowak A. Acne inversa (hidradenitis suppurativa): a review with a focus on pathogenesis and treatment. Indian Dermatol Online J. 2013;4:2.

    PubMed Central  PubMed  Article  Google Scholar 

  21. 21.

    Van der Zee HH, Prens EP, Boer J. Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. J Am Acad Dermatol. 2010;63:475–80.

    PubMed  Article  Google Scholar 

  22. 22.

    Esmann S, Jemec GBE. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol. 2011;91:328–32.

    PubMed  Article  Google Scholar 

  23. 23.

    Von der Werth JM, Jemec GBE. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol. 2001;144:809–13.

    PubMed  Article  Google Scholar 

  24. 24.

    Onderdijk AJ, van der Zee HH, Esmann S, Lophaven S, Dufour DN, Jemec GBE, et al. Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2013;27:473–8

    Google Scholar 

  25. 25.

    Kurek A, Peters EMJ, Chanwangpong A, Sabat R, Sterry W, Schneider-Burrus S. Profound disturbances of sexual health in patients with acne inversa. J Am Acad Dermatol. 2012;67:422–8.

    PubMed  Article  Google Scholar 

  26. 26.

    Fitzsimmons JS, Guilbert PR, Fitzsimmons EM. Evidence of genetic factors in hidradenitis suppurativa. Br J Dermatol. 1985;113:1–8.

    CAS  PubMed  Article  Google Scholar 

  27. 27.

    Cosmatos I, Matcho A, Weinstein R, Montgomery MO, Stang P. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2013;69:819

    Google Scholar 

  28. 28.

    • Vazquez BG, Alikhan A, Weaver AL, Wetter DA, Davis MD. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol. 2012;133:97–103. This was the first study that investigated the incidence of HS.

    PubMed Central  PubMed  Article  Google Scholar 

  29. 29.

    • Van der Zee HH, Laman JD, Boer J, Prens EP. Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments. Exp Dermatol. 2012;21:735–9. This comprehensive review article presents a new, well-explained hypothesis on the pathogenesis of HS.

    PubMed  Google Scholar 

  30. 30.

    Jemec GBE, Hansen U. Histology of hidradenitis suppurativa. J Am Acad Dermatol. 1996;34:994–9.

    CAS  PubMed  Article  Google Scholar 

  31. 31.

    Kamp S, Fiehn AM, Stenderup K, Rosada C, Pakkenberg B, Kemp K, et al. Hidradenitis suppurativa: a disease of the absent sebaceous gland? Sebaceous gland number and volume are significantly reduced in uninvolved hair follicles from patients with hidradenitis suppurativa. Br J Dermatol. 2011;164:1017–22.

    CAS  PubMed  Article  Google Scholar 

  32. 32.

    Pink AE, Simpson MA, Brice GW, Smith CH, Desai N, Mortimer PS, et al. PSENEN and NCSTN mutations in familial hidradenitis suppurativa (Acne Inversa). J Invest Dermatol. 2011;131:1568–70.

    CAS  PubMed  Article  Google Scholar 

  33. 33.

    •• Pink AE, Simpson MA, Desai N, Trembath RC, Barker JNW. γ-secretase mutations in hidradenitis suppurativa: new insights into disease pathogenesis. J Invest Dermatol. 2012;133:601–7. This article gives an excellent overview about the mutations found in HS.

    PubMed  Article  Google Scholar 

  34. 34.

    Wang B, Yang W, Wen W, Sun J, Su B, Liu B, et al. γ-secretase gene mutations in familial acne inversa. Science. 2010;330:1065.

    CAS  PubMed  Article  Google Scholar 

  35. 35.

    Melnik BC, Plewig G. Impaired Notch‐MKP‐1 signalling in hidradenitis suppurativa: an approach to pathogenesis by evidence from translational biology. Exp Dermatol. 2013;22:172–7.

    CAS  PubMed  Article  Google Scholar 

  36. 36.

    Van der Zee HH, Van Der Woude CJ, Florencia EF, Prens EP. Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study. Br J Dermatol. 2010;162:195–7.

    PubMed  Article  Google Scholar 

  37. 37.

    Nazary M, van der Zee HH, Prens EP, Folkerts G, Boer J. Pathogenesis and pharmacotherapy of Hidradenitis suppurativa. Eur J Pharmacol. 2011;672:1–8.

    CAS  PubMed  Article  Google Scholar 

  38. 38.

    Schlapbach C, Hänni T, Yawalkar N, Hunger RE. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011;65:790–8.

    CAS  PubMed  Article  Google Scholar 

  39. 39.

    Van der Zee HH, Laman JD, de Ruiter L, Dik WA, Prens EP. Adalimumab (antitumour necrosis factor‐α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study. Br J Dermatol. 2012;166:298–305.

    PubMed  Article  Google Scholar 

  40. 40.

    Dréno B, Khammari A, Brocard A, Moyse D, Blouin E, Guillet G, et al. Hidradenitis suppurativa: the role of deficient cutaneous innate immunity. Arch Dermatol. 2012;148:182.

    PubMed  Article  Google Scholar 

  41. 41.

    Hunger RE, Surovy AM, Hassan AS, Braathen LR, Yawalkar N. Toll‐like receptor 2 is highly expressed in lesions of acne inversa and colocalizes with C‐type lectin receptor. Br J Dermatol. 2008;158:691–7.

    CAS  PubMed  Article  Google Scholar 

  42. 42.

    Hofmann SC, Saborowski V, Lange S, Kern WV, Bruckner-Tuderman L, Rieg S. Expression of innate defense antimicrobial peptides in hidradenitis suppurativa. J Am Acad Dermatol. 2012;66:966–74.

    CAS  PubMed  Article  Google Scholar 

  43. 43.

    Schlapbach C, Yawalkar N, Hunger RE. Human β-defensin-2 and psoriasin are overexpressed in lesions of acne inversa. J Am Acad Dermatol. 2009;61:58–65.

    CAS  PubMed  Article  Google Scholar 

  44. 44.

    Emelianov VU, Bechara FG, Gläser R, Langan EA, Taungjaruwinai WM, Schröder JM, et al. Immunohistological pointers to a possible role for excessive cathelicidin (LL‐37) expression by apocrine sweat glands in the pathogenesis of hidradenitis suppurativa/acne inversa. Br J Dermatol. 2012;166:1023–34.

    CAS  PubMed  Article  Google Scholar 

  45. 45.

    Wolk K, Warszawska K, Hoeflich C, Witte E, Schneider-Burrus S, Witte K, et al. Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol. 2011;186:1228–39.

    CAS  PubMed  Article  Google Scholar 

  46. 46.

    Mortimer PS, Dawber RP, Gales MA, Moore RA. Mediation of hidradenitis suppurativa by androgens. Br Med J (Clin Res Ed). 1986;292:245.

    CAS  Article  Google Scholar 

  47. 47.

    Jemec GBE. The symptomatology of hidradenitis suppurativa in women. Br J Dermatol. 1988;119:345–50.

    CAS  PubMed  Article  Google Scholar 

  48. 48.

    Barth JH, Layton AM, Cunliffe WJ. Endocrine factors in pre‐and postmenopausal women with hidradenitis suppurativa. Br J Dermatol. 1996;134:1057–9.

    CAS  PubMed  Article  Google Scholar 

  49. 49.

    Harrison BJ, Read GF, Hughes LE. Endocrine basis for the clinical presentation of hidradenitis suppurativa. Br J Surg. 1988;75:972–5.

    CAS  PubMed  Article  Google Scholar 

  50. 50.

    Sartorius K, Emtestam L, Jemec GBE, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. 2009;161:831–9.

    CAS  PubMed  Article  Google Scholar 

  51. 51.

    König A, Lehmann C, Rompel R, Happle R. Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology. 1999;198:261–4.

    PubMed  Article  Google Scholar 

  52. 52.

    Kurzen H, Kurokawa I, Jemec GBE, Emtestam L, Sellheyer K, Giamarellos-Bourboulis EJ, et al. What causes hidradenitis suppurativa? Exp Dermatol. 2008;17:455–6.

    CAS  PubMed  Article  Google Scholar 

  53. 53.

    Happle R, König A. Smoker’s boils. Dermatology. 2011;222:282–4.

    PubMed  Article  Google Scholar 

  54. 54.

    Blandina P, Fantozzi R, Mannaioni PF, Masini E. Characteristics of histamine release evoked by acetylcholine in isolated rat mast cells. J Physiol. 1980;301:281–93.

    CAS  PubMed  Google Scholar 

  55. 55.

    Sørensen LT, Nielsen HB, Kharazmi A, Gottrup F. Effect of smoking and abstention on oxidative burst and reactivity of neutrophils and monocytes. Surgery. 2004;136:1047–53.

    PubMed  Article  Google Scholar 

  56. 56.

    Aoshiba K, Nagai A, Yasui S, Konno K. Nicotine prolongs neutrophil survival by suppressing apoptosis. J Lab Clin Med. 1996;127:186–94.

    CAS  PubMed  Article  Google Scholar 

  57. 57.

    Hana A, Booken D, Henrich C, Gratchev A, Maas-Szabowski N, Goerdt S, et al. Functional significance of non-neuronal acetylcholine in skin epithelia. Life Sci. 2007;80:2214–20.

    CAS  PubMed  Article  Google Scholar 

  58. 58.

    Matusiak Ł, Bieniek A, Szepietowski JC. Hidradenitis suppurativa and associated factors: still unsolved problems. J Am Acad Dermatol. 2009;61:362–5.

    PubMed  Article  Google Scholar 

  59. 59.

    Simonart T. Hidradenitis suppurativa and smoking. J Am Acad Dermatol. 2010;62:149–50.

    PubMed  Article  Google Scholar 

  60. 60.

    Yosipovitch G, DeVore A, Dawn A. Obesity and the skin: skin physiology and skin manifestations of obesity. J Am Acad Dermatol. 2007;56:901–16.

    PubMed  Article  Google Scholar 

  61. 61.

    Coppack SW. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc Lond 2001;60:349–56.

    Google Scholar 

  62. 62.

    Yazdanyar S, Jemec GBE. Hidradenitis suppurativa: a review of cause and treatment. Curr Opin Infect Dis. 2011;24:118–23.

    PubMed  Article  Google Scholar 

  63. 63.

    Van der Zee HH, Boer J, Prens EP, Jemec GBE. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology. 2009;219:143–7.

    PubMed  Article  Google Scholar 

  64. 64.

    Bettoli V, Zauli S, Borghi A, Toni G, Minghetti S, Ricci M, et al. Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa‐acne inversa: a prospective study on 23 patients. J Eur Acad Dermatol Venereol. 2013. doi: 10.1111/jdv.12127.

  65. 65.

    Morgan WP, Leicester G. The role of depilation and deodorants in hidradenitis suppurativa. Arch Dermatol. 1982;118:101.

    CAS  PubMed  Article  Google Scholar 

  66. 66.

    Dufour DN, Bryld LE, Jemec GBE. Hidradenitis suppurativa complicating naevus comedonicus: the possible influence of mechanical stress on the development of hidradenitis suppurativa. Dermatology. 2010;220:323–5.

    PubMed  Article  Google Scholar 

  67. 67.

    De Winter K, van der Zee HH, Prens EP. Is mechanical stress an important pathogenic factor in hidradenitis suppurativa? Exp Dermatol. 2012;21:176–7.

    PubMed  Article  Google Scholar 

  68. 68.

    Chicarilli ZN. Follicular occlusion triad: hidradenitis suppurativa, acne conglobata, and dissecting cellulitis of the scalp. Ann Plast Surg. 1987;18:230–7.

    CAS  PubMed  Article  Google Scholar 

  69. 69.

    Scheinfeld NS. A case of dissecting cellulitis and a review of the literature. Dermatol Online J. 2003;9:8

    Google Scholar 

  70. 70.

    Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol. 2010;2:9–16.

    PubMed Central  PubMed  Article  Google Scholar 

  71. 71.

    Canoui-Poitrine F, Le Thuaut A, Revuz JE, Viallette C, Gabison G, Poli F, et al. Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study. J Invest Dermatol. 2013;133:1506–11

    Google Scholar 

  72. 72.

    Church JM, Fazio VW, Lavery IC, Oakley JR, Milsom JW. The differential diagnosis and comorbidity of hidradenitis suppurativa and perianal Crohn’s disease. Int J Colorectal Dis. 1993;8:117–9.

    CAS  PubMed  Article  Google Scholar 

  73. 73.

    Yazdanyar S, Miller IM, Jemec GB. Hidradenitis suppurativa and Crohn’s disease: two cases that support an association. Acta Dermatovenerol Alp Panonica Adriat. 2010;19:23–5

    Google Scholar 

  74. 74.

    Hsiao JL, Antaya RJ, Berger T, Maurer T, Shinkai K, Leslie KS. Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review. Arch Dermatol. 2010;146:1265–70.

    PubMed  Google Scholar 

  75. 75.

    Ruocco E, Sangiuliano S, Gravina AG, Miranda A, Nicoletti G. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatology Venereol. 2009;23:1008–17.

    CAS  Article  Google Scholar 

  76. 76.

    Bhalla R, Sequeira W. Arthritis associated with hidradenitis suppurativa. Ann Rheum Dis. 1994;53:64–6.

    CAS  PubMed  Article  Google Scholar 

  77. 77.

    Leybishkis B, Fasseas P, Ryan KF, Roy R. Hidradenitis suppurativa and acne conglobata associated with spondyloarthropathy. Am J Med Sci. 2001;321:195–7.

    CAS  PubMed  Article  Google Scholar 

  78. 78.

    Thein M, Hogarth MB, Acland K. Seronegative arthritis associated with the follicular occlusion triad. Clin Exp Dermatol. 2004;29:550–2.

    CAS  PubMed  Article  Google Scholar 

Download references

Acknowledgments

We would like to thank A.M.R. Schrader for her contribution to this article.

Compliance with Ethics Guidelines

Conflict of Interest

I.E. Deckers declares no conflicts of interest.

H.H. van der Zee declares no conflicts of interest.

E.P. Prens is on the advisory board for AbbVie; is a consultant for AbbVie, Novartis, and Astra Zeneca; has developed educational material for Astra Zeneca; and has received research support from Pfizer.

Human and Animal Rights and Informed Consent

All studies by H.H. van der Zee and E.P. Prens involving animal and/or human subjects were performed after approval by the appropriate institutional review boards. When required, written informed consent was obtained from all participants.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Errol P. Prens.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Deckers, I.E., van der Zee, H.H. & Prens, E.P. Epidemiology of Hidradenitis Suppurativa: Prevalence, Pathogenesis, and Factors Associated with the Development of HS. Curr Derm Rep 3, 54–60 (2014). https://doi.org/10.1007/s13671-013-0064-8

Download citation

Keywords

  • Hidradenitis suppurativa
  • Acne inversa
  • Epidemiology
  • Prevalence
  • Smoking
  • Obesity
  • Genetics
  • Immunology